{
    "nct_id": "NCT03755804",
    "official_title": "Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17",
    "inclusion_criteria": "* Histologically confirmed, previously untreated CD30+ classical HL. (Participants are still eligible if they received limited emergent RT or steroid therapy - maximum of 7 days if within the last month or as approved by PI).\n* Age ≤ 21 years at the time of diagnosis (i.e., participants are eligible until their 22nd birthday) for low-risk and intermediate-risk\n* Age ≤ 25 years at the time of diagnosis (i.e., participants are eligible until their 26th birthday) for high-risk\n* All Ann Arbor stages.\n\n  * Low-Risk: IA, IIA (excluding patients with \"E\" lesions or mediastinal bulk)\n  * Intermediate-Risk: IA or IIA with \"E\" lesions or bulky mediastinal adenopathy (mediastinal mass to thoracic cavity ratio 33% or greater by chest radiograph) and IB, IIIA.\n  * High-Risk: IIB, IIIB, IV\n* Adequate renal function based on GFR ≥ 70 ml/min/1.73m2 OR serum creatinine adjusted for age and gender as follows: Age 1 to < 2 years: maximum serum creatinine 0.6 mg/dL for males and 0.6 mg/dL for females, Age 2 to < 6 years: maximum serum creatinine 0.8 mg/dL for males and 0.8 mg/dL for females, Age 6 to < 10 years: maximum serum creatinine 1 mg/dL for males and 1 mg/dL for females, Age 10 to < 13 years: maximum serum creatinine 1.2 mg/dL for males and 1.2 mg/dL for females, Age 13 to < 16 years: maximum serum creatinine 1.5 mg/dL for males and 1.4 mg/dL for females, Age ≥16 years: maximum serum creatinine 1.7 mg/dL for males and 1.4 mg/dL for females\n* Adequate hepatic function (total bilirubin ≤ 1.5 x ULN for age, and AST/ALT ≤ 2.5 x ULN for age).\n* Adequate hematologic criteria at baseline, unless secondary to Hodgkin disease diagnosis\n\n  * Absolute neutrophil count (ANC) ≥1000/µL\n  * Platelets ≥ 75,000/µL\n* Adequate cardiac function defined as shortening fraction of ≥ 27% by echocardiogram or MUGA, unless decreased function is due to large mediastinal mass or effusion related to HL.\n* Adequate pulmonary function defined as no evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry > 92% on room air unless secondary to a large mediastinal mass or effusion related to HL.\n* Female participant who is post-menarchal must have a negative urine or serum pregnancy test.\n* Female or male participant of reproductive potential must agree to use an effective contraceptive method throughout duration of study treatment.\nHealthy volunteers allowed\nMust have maximum age of 25 Years",
    "exclusion_criteria": "* CD30 negative HL.\n* Has received prior therapy for Hodgkin lymphoma\n* Inadequate organ function\n* High-risk participants with a history of ≥ grade 2 peripheral neuropathy or any active neurologic disease that would impede the ability to assess neurologic toxicities.\n* Inability or unwillingness of research participant or legal guardian / representative to give written informed consent.",
    "miscellaneous_criteria": ""
}